PATTERNS OF CARE FOR HODGKIN LYMPHOMA IN BRAZIL- REAL WORLD DATA (RWD) FROM A PRIVATE HEALTHCARE SYSTEM
Author(s)
Zagadailov E1, Andrade F2, Barreto T2, Gautam A3, Clark OA4, Saad R4, Seal B3, Dalal M1, Baiocchi O5
1Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, 2Takeda Farmacêutica Brasil, São Paulo, Brazil, 3Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, 4Evidencias - Kantar Health, Campinas, Brazil, 5Universidade Federal de São Paulo, São Paulo, Brazil
METHODS: This was a retrospective analysis of demographic, disease-related and treatment-related data for patients with HL. Patients were required to have a diagnosis for HL in Evidencias-Kantar Health claims database (Auditron, which covers 3+ million lives, ~7% of Brazilian private sector) between March/2013-March/2016. Data were analyzed using descriptive statistics.
RESULTS: CONCLUSIONS: ABVD was the most common first-line treatment regimen in this cohort of HL patients from the private healthcare setting in Brazil. Treatment patterns in second-line or latter lines were heterogenous and patients did not receive BV until third or later lines.
Conference/Value in Health Info
Value in Health, Vol. 20, No. 5 (May 2017)
Code
PCN220
Topic
Health Policy & Regulatory, Health Service Delivery & Process of Care
Topic Subcategory
Prescribing Behavior, Pricing Policy & Schemes, Treatment Patterns and Guidelines
Disease
Oncology